NASDAQ:MYL - Mylan Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $32.10 +0.26 (+0.82 %) (As of 02/20/2019 02:06 AM ET)Previous Close$31.84Today's Range$31.72 - $32.1052-Week Range$26.03 - $44.18Volume2.57 million shsAverage Volume4.41 million shsMarket Capitalization$16.55 billionP/E Ratio7.04Dividend YieldN/ABeta1.63 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Receive MYL News and Ratings via Email Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MYL Previous Symbol CUSIP62853010 Webwww.mylan.com Phone44-0-17-0785-3000Debt Debt-to-Equity Ratio1.20 Current Ratio1.26 Quick Ratio0.77Price-To-Earnings Trailing P/E Ratio7.04 Forward P/E Ratio6.93 P/E Growth1.08 Sales & Book Value Annual Sales$11.91 billion Price / Sales1.39 Cash Flow$8.1472 per share Price / Cash Flow3.94 Book Value$24.81 per share Price / Book1.29Profitability EPS (Most Recent Fiscal Year)$4.56 Net Income$696 million Net Margins4.71% Return on Equity19.39% Return on Assets7.15%Miscellaneous Employees35,000 Outstanding Shares515,631,000Market Cap$16.55 billion OptionableOptionable Mylan (NASDAQ:MYL) Frequently Asked Questions What is Mylan's stock symbol? Mylan trades on the NASDAQ under the ticker symbol "MYL." How were Mylan's earnings last quarter? Mylan NV (NASDAQ:MYL) released its earnings results on Wednesday, August, 8th. The company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.22 by $0.15. The firm had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.95 billion. Mylan had a return on equity of 19.39% and a net margin of 4.71%. Mylan's revenue was down 5.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.10 EPS. View Mylan's Earnings History. When is Mylan's next earnings date? Mylan is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Mylan. What price target have analysts set for MYL? 15 equities research analysts have issued 1 year price targets for Mylan's stock. Their forecasts range from $31.00 to $59.00. On average, they anticipate Mylan's share price to reach $43.5385 in the next twelve months. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for Mylan. What is the consensus analysts' recommendation for Mylan? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan. What are Wall Street analysts saying about Mylan stock? Here are some recent quotes from research analysts about Mylan stock: 1. According to Zacks Investment Research, "Mylan is exploring the world of biosimilars, a market that has the huge potential. A partnership with Biocon, and collaborations with Momenta and Mabion has helped Mylan develop a portfolio of 20 biosimilar/insulin analog generic products,. The company has launched nearly 475 products year to date across its segments, including a record number of complex generics and biosimilars. In August 2018, Mylan completed an agreement with certain subsidiaries of Novartis to purchase worldwide rights to their global cystic fibrosis products, consisting of the TOBI Podhaler and TOBI solution. This should further broaden the company’s portfolio. However, Mylan proactively discontinued a number of products, while also transferring some to other sites. These have led to a temporary disruption in supply of certain products and reduced volumes in North America Shares have underperformed the industry in the last six months." (1/23/2019) 2. Cantor Fitzgerald analysts commented, "We rate MYL as 12-month price target of $41. We like the company, and there are a lot of potentially positive catalysts coming up. That said, the risk reward is already reflected in the stock’s valuation, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to calculate our 12- month price target of $41." (11/20/2018) 3. Guggenheim analysts commented, "We spoke with two oncologists in different practice settings regarding their potential use of Fulphila. While biosimilar financial incentives will play a role in Fulphila’s adoption, the Onpro device appears entrenched in current clinical practice. For that and other reasons, we believe that it might be more prudent to take a conservative approach to Fulphila’s uptake at the outset. We maintain our BUY rating on shares of Mylan. Consultant Commentary: We spoke with two oncologists on their respective academic and rural private practice settings. The academic consultant saw roughly 100 Neulasta patients per month while the rural oncologist saw ~30 Neulasta patients per month." (6/14/2018) Has Mylan been receiving favorable news coverage? Media stories about MYL stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mylan earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Mylan's key competitors? Some companies that are related to Mylan include Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF) and Merck KGaA (MKGAF). Who are Mylan's key executives? Mylan's management team includes the folowing people: Ms. Heather Bresch, CEO & Exec. Director (Age 50)Mr. Rajiv Malik, Pres & Exec. Director (Age 58)Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 46)Mr. Anthony Mauro, Chief Commercial Officer (Age 46) Who are Mylan's major shareholders? Mylan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.75%), Pzena Investment Management LLC (4.06%), Bank of New York Mellon Corp (1.92%), Geode Capital Management LLC (1.53%), Oregon Public Employees Retirement Fund (1.19%) and Dimensional Fund Advisors LP (1.19%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan. Which major investors are selling Mylan stock? MYL stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Carmignac Gestion, Orbimed Advisors LLC, Pzena Investment Management LLC, Bellevue Group AG, Bank of New York Mellon Corp, Millennium Management LLC and Tekla Capital Management LLC. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan. Which major investors are buying Mylan stock? MYL stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, State of Tennessee Treasury Department, Geode Capital Management LLC, BlackRock Inc., Squarepoint Ops LLC, Toronto Dominion Bank, Dimensional Fund Advisors LP and Canada Pension Plan Investment Board. View Insider Buying and Selling for Mylan. How do I buy shares of Mylan? Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mylan's stock price today? One share of MYL stock can currently be purchased for approximately $32.10. How big of a company is Mylan? Mylan has a market capitalization of $16.55 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe. What is Mylan's official website? The official website for Mylan is http://www.mylan.com. How can I contact Mylan? Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected] MarketBeat Community Rating for Mylan (NASDAQ MYL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 662 (Vote Outperform)Underperform Votes: 520 (Vote Underperform)Total Votes: 1,182MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What is insider trading?